Jarmella Russell, MD
Internal Medicine · Smithfield, NCNPI 1841589991
Payments from drug & device makers
Across 198 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$853
- Boehringer Ingelheim$448
- AbbVie$444
- Teva Pharmaceuticals USA, Inc.$441
- AstraZeneca$435
- Lilly USA, LLC$387
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $853 |
| Boehringer Ingelheim | 25 | $448 |
| AbbVie | 20 | $444 |
| Teva Pharmaceuticals USA, Inc. | 4 | $441 |
| AstraZeneca | 15 | $435 |
| Lilly USA, LLC | 17 | $387 |
| GSK | 8 | $307 |
| Amgen | 11 | $254 |
| Pfizer | 8 | $137 |
| Exact Sciences | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $102 |
| Medtronic | 1 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Abbott | 2 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Johnson & Johnson | 3 | $48 |
| Merck | 3 | $39 |
| Eisai Inc. | 3 | $38 |
| Astellas Pharma US Inc | 1 | $28 |
| Novartis | 2 | $28 |
| Gilead | 1 | $24 |
| Kvk-tech, Inc. | 3 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,509 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $163,924 |
| JardianceEmpagliflozin | 109 | $121,809 |
| EliquisApixaban | 80 | $80,287 |
| RybelsusSemaglutide | 58 | $79,357 |
| LinzessLinaclotide | 67 | $57,294 |
| MounjaroTirzepatide | 39 | $50,931 |
| TrulicityDulaglutide | 21 | $28,025 |
| JanuviaSitagliptin Phosphate | 15 | $20,270 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $19,769 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $18,906 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $14,324 |
| XareltoRivaroxaban | 21 | $14,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,483 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,546 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $853 | $243,281199 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $448 | $146,290146 claims |
| PfizerEliquis | $137 | $80,28780 claims |
| Lilly USA, LLCMounjaro, Trulicity | $387 | $78,95560 claims |
| AbbVieLinzess | $444 | $57,29467 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $307 | $36,24963 claims |
| MerckJanuvia | $39 | $20,27015 claims |
| Johnson & JohnsonXarelto | $48 | $14,16121 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $8,33311 claims |
| AstraZenecaSymbicort | $435 | $8,15830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Smithfield
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.